Table 1.

Cytotoxicity of cAC10-vcMMAE and free MMAE on CD30+ and CD30 tumor lines





IC50
Cell line
Lineage
Binding ratio
cAC10-vcMMAE, ng/mL
MMAE, nM
L540   Hodgkin disease, T-cell like   318   9.88 ± 2.49 (n=4)   0.21 ± 0.12 (n = 3)  
Karpas   Anaplastic large cell lymphoma   163   1.29 ± 0.46 (n=5)   0.073 ± 0.05 (n = 5)  
HDLM2   Hodgkin disease, T-cell like   147   302 ± 177 (n=4)   0.072 ± 0.03 (n = 4)  
HH   Cutaneous T-cell lymphoma   73   2.0 ± 1.7 (n=3)   0.27 ± 0.09 (n = 3)  
SU-DHL-1   Anaplastic large cell lymphoma   54   0.54 ± 0.19 (n=4)   0.039 ± 0.015 (n = 4)  
Raji   Burkitt lymphoma B cell   2   8701 ± 666 (n=3)   0.14 ± 0.07 (n = 3)  
Ramos   Burkitt lymphoma B cell   0.9   3333 ± 682 (n=3)   0.039 ± 0.02 (n = 4)  
Daudi
 
Burkitt lymphoma B cell
 
1
 
7500 ± 443 (n=3)
 
1.35 ± 0.31 (n = 3)
 




IC50
Cell line
Lineage
Binding ratio
cAC10-vcMMAE, ng/mL
MMAE, nM
L540   Hodgkin disease, T-cell like   318   9.88 ± 2.49 (n=4)   0.21 ± 0.12 (n = 3)  
Karpas   Anaplastic large cell lymphoma   163   1.29 ± 0.46 (n=5)   0.073 ± 0.05 (n = 5)  
HDLM2   Hodgkin disease, T-cell like   147   302 ± 177 (n=4)   0.072 ± 0.03 (n = 4)  
HH   Cutaneous T-cell lymphoma   73   2.0 ± 1.7 (n=3)   0.27 ± 0.09 (n = 3)  
SU-DHL-1   Anaplastic large cell lymphoma   54   0.54 ± 0.19 (n=4)   0.039 ± 0.015 (n = 4)  
Raji   Burkitt lymphoma B cell   2   8701 ± 666 (n=3)   0.14 ± 0.07 (n = 3)  
Ramos   Burkitt lymphoma B cell   0.9   3333 ± 682 (n=3)   0.039 ± 0.02 (n = 4)  
Daudi
 
Burkitt lymphoma B cell
 
1
 
7500 ± 443 (n=3)
 
1.35 ± 0.31 (n = 3)
 

Lineages as listed in Gruss et al.22 

Binding ratios were determined by dividing the geometric mean fluorescence intensity of cells stained with cAC10 and secondary (goat-antihuman immunoglobulin)-FITC conjugate by the geometric mean fluorescence intensity of cells stained with secondary antibody alone.

IC50 results are expressed as mean ± SEM.

Values in parentheses represent number of experiments, with each experimental result an average of quadruplicate determinations.

Close Modal

or Create an Account

Close Modal
Close Modal